The CRO mad­ness con­tin­ues as Gold­man Sachs-backed buy­er group shells out $8.5B for Parex­el

The Covid-19 pan­dem­ic has kicked the con­tract re­search field in­to high gear, with a par­tic­u­lar fo­cus on de­cen­tral­ized tri­als as the re­search tool of the fu­ture. With so much work — and cash — fly­ing around, some deep-pock­et­ed in­vestors are sign­ing big checks to get in on the game.

Count Gold­man Sachs among them.

Gold­man Sachs’ pri­vate eq­ui­ty branch and the EQT IX fund will pay $8.5 bil­lion to ac­quire CRO Parex­el as part of a buy­out that con­tin­ues a hot run of M&A in the boom­ing field of con­tract re­search, the com­pa­ny con­firmed Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER